Semax: The Complete Research Guide (2026)

Semax (ACTH(4-7)-Pro-Gly-Pro) is a synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH). Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it has become one of the most actively studied nootropic and neuroprotective peptides in modern research. Unlike full-length ACTH, Semax carries no corticotropic activity - it does not stimulate cortisol production or affect adrenal function. Instead, its research interest centers on robust effects on neurotrophin expression, melanocortin receptor signaling, and gene regulation in the central nervous system.

What Is Semax and Why Does It Matter?

Semax's amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues (Met-Glu-His-Phe) correspond to the ACTH(4-7) fragment, which is the minimal sequence responsible for ACTH's neurotrophic effects. The C-terminal Pro-Gly-Pro tripeptide was added specifically to increase resistance to enzymatic degradation by prolyl endopeptidases and other serum proteases.

This design choice is critical. Native ACTH(4-10) fragments break down within seconds in the bloodstream. The Pro-Gly-Pro tail extends Semax's functional window enough to produce measurable biological effects, making it viable as a research tool.

In Russia, Semax has been approved as a prescription medication since 2001 for conditions including cognitive impairment and ischemic stroke recovery. In Western research settings, it remains an investigational compound, but one with a growing body of peer-reviewed literature behind it.

Mechanism of Action: How Semax Works

Semax's pharmacology involves several overlapping molecular pathways. Rather than acting on a single receptor target, it influences broad patterns of gene expression and neurotrophin signaling.

Melanocortin System Activation

Semax interacts with the melanocortin receptor system, particularly MC4R and potentially MC3R. The melanocortin system is involved in a wide range of CNS functions including learning, memory, attention, and neuroprotection. Unlike Melanotan II (a potent pan-melanocortin agonist), Semax shows a more selective and moderate activation profile, which may explain its favorable tolerability in research models.

A 2024 study by Inozemtseva et al. directly compared Semax and Melanotan II as ACTH(4-10) analogs and found that both peptides reversed chronic stress-induced anhedonia and restored hippocampal BDNF levels in rats, confirming the melanocortin pathway as a key mediator of Semax's effects (Inozemtseva et al., 2024).

BDNF Upregulation

The most well-documented molecular effect of Semax is its ability to increase Brain-Derived Neurotrophic Factor (BDNF) expression. BDNF is the brain's primary growth factor for neuronal survival, synaptic plasticity, and long-term memory formation.

Research has shown that Semax administration elevates BDNF mRNA and protein levels in the hippocampus, frontal cortex, and cerebellum. Stavchansky et al. (2011) demonstrated that both Semax and its C-terminal Pro-Gly-Pro fragment independently influenced the expression of neurotrophins (NGF, BDNF, NT-3) and their receptors (TrkA, TrkB, TrkC, p75) in rat brain regions following ischemia (Stavchansky et al., 2011).

This BDNF connection is significant because reduced BDNF levels are consistently implicated in cognitive decline, depression, and neurodegenerative conditions across the research literature.

Gene Expression Modulation

High-throughput RNA sequencing studies have revealed that Semax's effects extend far beyond a single pathway. Filippenkov et al. (2024) used RNA-Seq to identify 258 differentially expressed genes in the rat frontal cortex following Semax administration, with significant modulation of genes related to neurotransmitter signaling, inflammatory response, and neuroplasticity (Filippenkov et al., 2024).

This broad transcriptomic impact suggests Semax acts more like a systems-level modulator than a conventional single-target drug - a characteristic that makes it particularly interesting for complex neuroscience research.

Neuroprotective Signaling

In ischemia models, Semax has demonstrated consistent neuroprotective effects. It reduces infarct volume, preserves neuronal viability, and attenuates the inflammatory gene cascade that follows stroke-like events in animal models. The neuroprotection appears to involve both direct neurotrophin support and modulation of the immune-inflammatory response in brain tissue.

Semax vs. Selank: A Detailed Comparison

Researchers frequently compare Semax and Selank because both are Russian-developed neuropeptides with nootropic properties. However, their mechanisms and optimal research applications differ substantially.

Origin and structure: Semax derives from ACTH, the stress-response hormone. Selank derives from tuftsin, an immune-modulating peptide. This fundamental difference shapes everything about how they work.

Primary effects: Semax leans toward cognitive stimulation and neuroprotection. It tends to increase alertness, focus, and information processing in animal models. Selank leans toward anxiolytic and calming nootropic effects, working primarily through GABA modulation and serotonin metabolism.

BDNF influence: Both peptides affect BDNF, but through different upstream pathways. Semax works through melanocortin signaling and direct neurotrophin gene regulation. Selank works through stress-response normalization and immune modulation.

Stimulation profile: In behavioral studies, Semax tends to increase exploratory behavior and active coping strategies. Selank reduces anxiety-driven avoidance without sedation. For researchers studying cognitive enhancement in non-anxious models, Semax may be more directly relevant. For anxiety-cognition interactions, Selank may be the better tool.

Complementary use: Some research protocols investigate both peptides together, leveraging their non-overlapping mechanisms. Semax provides the stimulatory nootropic component while Selank provides anxiolytic balance. This is an active area of investigation in combination peptide research.

Pharmacokinetics and Stability

Semax presents an interesting pharmacokinetic profile. Its plasma half-life in free form is short - approximately 2 to 3 minutes - due to enzymatic cleavage despite the stabilizing Pro-Gly-Pro tail. However, the biological effects persist far longer than the peptide itself remains in circulation.

This disconnect between plasma half-life and duration of effect is explained by Semax's mechanism. Once it triggers BDNF upregulation and gene expression changes, those downstream effects continue for hours to days. The peptide acts as an initiator of cascading molecular events rather than a sustained-presence drug.

Degradation products are also active. The C-terminal Pro-Gly-Pro fragment released during Semax metabolism has its own documented biological activity, including independent effects on neurotrophin expression. This means the "breakdown" of Semax is not simply inactivation - it generates secondary active molecules.

Administration routes studied: Intranasal delivery is the most common route in published literature, taking advantage of direct nose-to-brain transport that bypasses the blood-brain barrier. Subcutaneous and intraperitoneal routes are also well-documented in animal research.

Research Applications and Findings

Cognitive Enhancement

Semax's nootropic effects have been documented across multiple cognitive domains in animal models:

• Memory consolidation - improved performance in passive avoidance and Morris water maze tasks
• Attention and processing speed - enhanced sustained attention in behavioral paradigms
• Learning rate - faster acquisition of novel tasks in conditioned response models
• Working memory - improved performance in delayed alternation tasks

These cognitive effects appear to be dose-dependent and are most pronounced in models of cognitive impairment rather than in healthy baseline animals, suggesting Semax restores or optimizes cognitive function rather than pushing it above normal limits.

Neuroprotection and Stroke Research

The most clinically advanced application of Semax is in ischemic stroke. Russian clinical trials have evaluated Semax as an adjunct therapy for stroke recovery, with results showing:

• Reduced neurological deficit scores when administered early post-stroke
• Elevated BDNF plasma levels correlating with improved rehabilitation outcomes (Gusev et al., 2018)
• Modulation of thousands of ischemia-disrupted genes in affected brain regions
• Attenuation of inflammatory cytokine cascades in the acute post-ischemic period

Antidepressant and Stress Research

The 2024 chronic unpredictable stress study by Inozemtseva et al. represents some of the most recent evidence for Semax's effects on mood-related pathways. At a low dose of 60 nmol/kg administered daily, Semax reversed stress-induced anhedonia, normalized body weight suppression, reduced adrenal hypertrophy, and restored hippocampal BDNF levels. Notably, these effects occurred without the typical side effects associated with conventional antidepressant compounds.

Reconstitution and Handling

Semax is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use in research protocols.

Reconstitution protocol: Follow standard peptide reconstitution procedures using bacteriostatic water. Direct the solvent stream against the vial wall rather than directly onto the peptide cake, and allow it to dissolve gently without vortexing. For a step-by-step walkthrough, see our complete reconstitution guide.

Storage: Lyophilized Semax should be stored at -20C for long-term stability. Once reconstituted, store at 2-8C and use within 30 days. Avoid repeated freeze-thaw cycles. For detailed storage protocols, refer to our peptide storage guide.

Quality verification: Always confirm peptide identity and purity before beginning research. A proper Certificate of Analysis should show purity of average 99.7% via HPLC, with mass spectrometry confirmation of molecular weight (813.93 Da for the free base). Not sure what to look for? Our guide on how to read a peptide COA breaks it down step by step.

Current Research Directions

Several areas of Semax research are gaining momentum heading into 2026 and beyond:

Transcriptomic profiling - High-throughput RNA-Seq studies are mapping the full scope of Semax's gene expression effects, revealing previously unknown pathways and potential therapeutic targets. This systems-level approach is replacing older single-pathway studies.

Combination protocols - Researchers are investigating Semax alongside other research peptides including Selank, BPC-157, and other neuroprotective compounds. The goal is to understand whether complementary mechanisms produce synergistic effects.

Novel delivery systems - Work on nanoparticle encapsulation and sustained-release formulations aims to address Semax's short plasma half-life while maintaining its favorable biological activity profile.

Neurodegenerative disease models - Preliminary research is exploring Semax in models of Alzheimer's and Parkinson's disease, given its BDNF-enhancing and anti-inflammatory properties. These studies are still early-stage but represent a logical extension of the neuroprotection data.

Frequently Asked Questions

What is Semax derived from?

Semax is a synthetic analog of the ACTH(4-10) fragment of adrenocorticotropic hormone, with an added Pro-Gly-Pro C-terminal tripeptide that improves its enzymatic stability. It retains the neurotrophic properties of ACTH without any corticotropic (cortisol-stimulating) activity.

How does Semax differ from Selank?

Semax is derived from ACTH and primarily targets cognitive enhancement and neuroprotection through melanocortin and BDNF pathways. Selank is derived from tuftsin and focuses more on anxiolytic effects through GABA modulation. They have complementary mechanisms and are sometimes studied together.

Does Semax affect BDNF levels?

Yes. Multiple published studies demonstrate that Semax administration increases Brain-Derived Neurotrophic Factor (BDNF) expression in the hippocampus and other brain regions in animal models. This is considered one of its primary mechanisms of action.

What is the half-life of Semax?

Semax has a relatively short plasma half-life of approximately 2 to 3 minutes in its free form. However, its biological effects persist significantly longer due to downstream signaling cascades - particularly BDNF upregulation and gene expression changes that continue for hours after the peptide itself has been cleared.

Is Semax approved for clinical use anywhere?

Semax is approved as a prescription medication in Russia for conditions including ischemic stroke recovery and cognitive disorders. In the United States and most Western countries, it is available strictly as a research compound and is not intended for human consumption.

References

1. Inozemtseva LS, Yatsenko KA, Glazova NY, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol. 2024;984:177068. doi:10.1016/j.ejphar.2024.177068

2. Filippenkov IB, Glazova NY, Sebentsova EA, et al. Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides. Biochemistry (Mosc). 2024;89(9):1643-1656. doi:10.1134/S0006297924090104

3. Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. doi:10.17116/jnevro20181183261-68

Ready to advance your peptide research? Browse our full catalog of research-grade peptides at Vantage Peptide - every compound ships with third-party verified COA documentation, HPLC purity testing, and mass spectrometry confirmation.

This article is for informational and research purposes only. Semax is sold as a research compound and is not intended for human consumption. Always comply with local regulations regarding peptide research.